Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

In its upcoming report, Pfizer (PFE) is predicted by Wall Street analysts to post quarterly earnings of $0.57 per share, reflecting a decline of 9.5% compared to the same period last year. Revenues ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

A Brussels court is weighing whether Poland must pay Pfizer €1.4 billion for undelivered COVID vaccines, in a case that could ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...